Goldring Centre for High Performance Sport at the University of Toronto
Toronto, Ontario, M5S2C9, Canada
NCT Number: NCT04887727
Previous studies have used a combination of oral L-[1-13C]leucine and intravenous labeled L-[5,5,5-2H3]leucine to assess the acute postprandial changes in whole-body protein turnover (12, 19). Intravenous and dietary-labeled amino acid tracers have also been used in tandem to assess rates of myofibrillar protein synthesis in response to bolus protein ingestion and resistance exercise (46). By validating whole-body net balance to myofibrillar protein synthesis, our proposed multi-tracer approach will develop minimally invasive models to study protein turnover in a variety of populations in which traditional infusions and/or repeated blood samples are not possible (i.e. pediatric, free-living populations).
Looking for future studies?
Notify Me18 year–35 year
Male
Interventional
Not applicable
Toronto, Ontario, M5S2C9, Canada
The primary objective of the proposed study is to validate the use of a novel oral tracer model to accurately and reliably measure myofibrillar protein synthesis. It is hypothesized that oral L-[1-13C]leucine and L-[ring-2H5]phenylalanine, ingested as a bolus to mimic an intravenous 'pulse dose' administration (51, 65), will reveal similar rates of myofibrillar protein synthesis when compared to traditional intravenous L-[5,5,5-2H3]leucine infusion. Moreover, it is hypothesized that both methods will reveal the expected graded changes in myofibrillar protein synthesis in response to feeding and resistance exercise (i.e. fasted<feeding<exercise & feeding).
The secondary objective of the proposed study is to develop and validate non-invasive models to measure whole-body amino acid oxidation and net balance in response to feeding and resistance exercise. It is hypothesized that whole-body net balance, as determined by a novel oral tracer model (i.e. L-[1-13C]leucine) , will align with traditional intravenous tracer methodology (i.e. L-[5,5,5-2H3]leucine) and reveal the expected physiological changes in whole-body protein turnover in response to feeding and resistance exercise (i.e. fasted<feeding<exercise & feeding).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Amino acid dose = 0.25g/kg bodyweight
Amino acid dose = 0.25g/kg bodyweight
Time frame: 5 hours
Myofibrillar protein synthesis rates assessed by oral and intravenous tracers during Fast, Fed, and Ex-Fed
Time frame: 5 hours
Whole-body protein turnover assessed by oral and intravenous tracers during Fast, Fed, and Ex-Fed
Time frame: 5 hours
Amino acid oxidation and net protein balance assessed by oral tracers during Fast, Fed, and Ex-Fed. Net protein balance is derived from the difference between amino acid intake (known) and total amino acid oxidation over the 5h measurement period.
Time frame: 2 and 5 hours
Immunoblotting for mTORC1/key downstream targets of mTORC1
Time frame: 2 and 5 hours
Immunoblotting for amino acid transporters LAT1/SNAT2
University of Toronto
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07612969
Healthy Adult Males, Healthy Subjects
Beirut, Lebanon
View Trial DetailsNCT05691660
Healthy Adult Males
Tokyo, Japan
View Trial DetailsNCT05396235
Healthy Adult Males
Shinjuku-ku, Tokyo, Japan
View Trial DetailsNCT02009917
Healthy Adult Males
Vancouver, British Columbia, Canada
View Trial Details